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Summary
Small series have suggested that split liver transplantation (SLT) has an increased
frequency of peri-operative acute kidney injury (AKI). However, the optimal
donor selection in this setting could have a favourable impact on renal outcomes.
This was a retrospective single-centre study of 76 adults who underwent SLT
(right extended lobe) and 301 adults who underwent elective full-size donation
after brain death liver transplantation (FSLT). SLT recipients were less likely than
unmatched FSLT recipients to develop AKI (≥stage 1 KDIGO criteria) (40.3% vs.
56.1%, P = 0.016) and had a reduced frequency of renal replacement therapy
(11.8% vs. 21.9%, P = 0.049). In 72 pairs of SLT patients and propensity risk
score-matched FSLT controls the incidence of AKI was not significantly different
(40.3% vs. 47.2%, P = 0.473). However, SLT patients were less likely to require
renal replacement therapy (11.1% vs. 23.6%, P = 0.078; adjusted OR 0.32; 95%
CI 0.11–0.87, P = 0.026). There was no association between SLT and the develop-
ment of chronic kidney disease (eGFR<60 ml/min/1.73 m2, log rank P = 0.534).
In conclusion, SLT is not associated with an increased frequency of AKI. These
observations support the postulation that the optimal donor status of SLT may
result in less graft injury with renal sparing effects.
Introduction
The growing discrepancy between supply and demand for
liver transplantation has necessitated the search for mea-
sures to increase the donor pool [1]. Split liver transplanta-
tion (SLT) is recommended as one such strategy, allowing
usually both an adult recipient and paediatric recipient to
benefit from a single organ [2,3]. In the UK, 15% of all
deceased donor liver transplants now use split livers [4].
However, in other countries such as the USA, SLT has been
less widely accepted because of inferior graft and recipient
survival compared with full-size donation after brain death
liver transplantation (FSLT) [5,6]. Larger volume centres
report acceptable outcomes [7–9]. Nevertheless, concerns
remain regarding the ethical implications of benefiting a
second recipient by increasing the morbidity and mortality
of the first [10].
Acute kidney injury (AKI) is a major cause of morbidity
and mortality after liver transplantation [11–14]. In addi-
tion to the prolonged recovery period and greater financial
cost, AKI is increasingly recognised as an independent risk
factor for short term mortality in the Intensive Care set-
ting [11,12,14,15]. Moreover, AKI can cause permanent
structural damage, with progressive tubulo-interstitial
fibrosis and long-term implications for renal function
[13,16–18]. Liver transplant recipients with postoperative
acute renal failure are twice as likely to develop chronic
kidney disease, which is associated with a 5-fold increased
risk of death [13].
The major reported morbidity of SLT relates to biliary
and vascular graft complications [6]. Renal outcomes after
SLT have been less well described. In two small studies
totalling 26 SLT recipients greater renal dysfunction was
demonstrated during the immediate post-operative period
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when SLT recipients and FSLT recipients were compared
[19,20]. Yet, the cohorts were not ideally matched, and the
observation was in the setting of an increased rate of graft-
related complications, including the need for re-operation
and sepsis. We have previously postulated that hepatic
ischaemia–reperfusion injury may play a critical role in the
pathogenesis of AKI following donation after circulatory
death (DCD) liver transplantation [14]. Following on from
this, we hypothesised that in SLT the optimal donor selec-
tion could have a beneficial renal sparing effect.
Our aim was to compare renal outcomes following SLT
with FSLT patients.
Methods
This was a retrospective single-centre study of 76 consecu-
tive adults who underwent SLT with a right extended lobe
graft (segments I and IV-VIII, split ex situ) and 301 consec-
utive patients who underwent FSLT for chronic liver dis-
ease between January 2007 and March 2011. The
implantation technique was piggyback in all cases. No SLT
or FSLT patient had a previous history of renal transplanta-
tion, and no patient received a combined liver–kidney
transplant. In view of the differing baseline clinical charac-
teristics of the two cohorts, a detailed comparison was per-
formed of 72 SLT patients and a control group of 72 FSLT
patients matched by propensity risk score (PRS).
Data were collected on the following donor and graft
variables: age, gender, height, aspartate aminotransferase
(AST), inotropes, warm ischaemic time and cold ischaemic
time. Donor risk index (DRI) was calculated as previously
described [21]. An allograft biopsy was performed immedi-
ately after reperfusion (time zero) in 28 SLT patients
(36.4%) and 217 FSLT patients (72.1%) and was graded by
an independent histopathologist.
The following recipient characteristics at the time of
admission for transplantation were recorded: age, gender,
ethnicity, additional co-morbidity including need for hae-
modialysis, international normalised ratio (INR), serum
bilirubin, serum creatinine, serum sodium and presence
of ascites (past history or ultrasonographic evidence).
Refractory ascites was defined according the International
Ascites Club criteria [22,23]. The MELD (Model for End-
Stage Liver Disease) score was determined [24]. The UK
Score for Patients with End-Stage Liver Disease
(UKELD), a recently devised scoring system that incorpo-
rates serum sodium in addition to the MELD variables
that is now used routinely in the UK to prioritise graft
allocation, was also calculated [25]. Intra-operative red
cell concentrate (RCC), fresh-frozen plasma (FFP) and
platelet transfusion requirements, and need for intra-
operative inotropes (noradrenaline/adrenaline infusion at
time of admission to the Intensive Care Unit). Docu-
mented peri-operative variables (following transplantation
but prior to hospital discharge) were peak serum AST,
peak serum creatinine, need for renal replacement ther-
apy and sepsis. Renal function was then recorded at 1, 3,
6, 9, 12, 18, 24, 30, 36, 42 and 48 months following
transplantation. Patients receiving renal replacement ther-
apy during the immediate post-operative period were
given a peak serum creatinine of three times baseline if
the actual recorded value was less [26]. Similarly, beyond
the peri-operative period patients on haemodialysis were
given an estimated glomerular filtration rate of 15 ml/
min/1.73 m2 [27].
Peri-operative acute renal dysfunction (following
transplantation but prior to hospital discharge) was
defined according to the KDIGO criteria for acute kid-
ney injury (AKI) and recent Working Party proposal: a
rise in serum creatinine by ≥26.5 lM in <48 h and/or
peak serum creatinine ≥1.5 times the baseline level
[28,29]. Stage 1, AKI was defined as a rise in serum cre-
atinine by ≥26.5 lM in <48 h and/or peak serum creati-
nine 1.5–1.9 times baseline; stage 2, AKI was defined as
peak serum creatinine 2.0–2.9 times baseline; stage 3,
AKI was defined as peak serum creatinine ≥3.0 times
baseline and/or increase in serum creatinine ≥353.6 lM
and/or renal replacement therapy [28]. The main mea-
sure of renal function thereafter was estimated glomeru-
lar filtration rate (eGFR), determined using the
Modification of Diet in Renal Disease (MDRD) Study
4-variable equation (eGFR = 186 9 creatinine(mg/
dl)1.154 9 age(years)0.203 9 1.212 (if black) 9 0.742
(if female) [30]. Chronic kidney disease was defined as
eGFR <60 ml/min/1.73 m2 on at least two occasions and
sustained from 6 months post-transplant onwards: stage
3, stage 4 and stage 5 chronic kidney disease were
defined as eGFR 30–59 ml/min/1.73 m2, 15–29 ml/min/
1.73 m2, and <15 ml/min/1.73 m2 or on dialysis, respec-
tively [27].
Immunosuppression was noted and calcineurin inhib-
itor trough levels at day-7, day-30 and 12-months.
Standard immunosuppression was tacrolimus aiming for
a trough level of 8–10 within the first 3 months of
transplantation, azathioprine and reducing dose steroid
discontinued by 3 months. Renal sparing immunosup-
pression consisted of half dose tacrolimus aiming for a
trough level of 5–8, mycophenolate and reducing dose
steroid discontinued by 3 months. In a single patient
(FSLT recipient), renal sparing with delayed introduc-
tion of calcineurin inhibitor and interleukin-2 receptor
antagonist cover was employed. No patient received si-
rolimus. All immunosuppression choices were Physician
and Surgeon dependent and made either prior to trans-
plantation or in the event of complications including
AKI. The tacrolimus trough levels on day 30 (renal
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sparing, 5.9 (2.4) lg/l; no renal sparing, 7.7 (4.1)
lg/l, mean (SD); P = 0.008) were lower in the patients
discharged on renal sparing immunosuppression, but
not at 12 months post-transplant (renal sparing, 6.9
(2.4) lg/l; no renal sparing, 6.1 (2.8) lg/l, mean (SD);
P = 0.161) (P < 0.025 considered significant).
Hepatic ischaemia–reperfusion injury minimising strate-
gies were not used in any donor. The decision to administer
intravenous n-acetylcysteine to the recipient was Surgeon
dependent and in all cases precipitated by clinical evidence
of initial poor graft function such as hemodynamic insta-
bility, lactic acidosis and/or high serum AST.
Statistical analyses
Matching patients by PRS is a recognised method of con-
trolling for selection bias [31,32]. A PRS for the allocation
of a split liver over a full-size liver amongst the 377 whole
liver transplant recipients (single organ) in our unit during
the time period studied was generated by nonparsimonious
multiple logistic regression. This model included all recipi-
ent variables of clinical relevance to the outcome measure
post-transplant AKI (age, gender, ethnicity, diagnosis, BMI,
diabetes mellitus, hypertension, ascites, eGFR, MELD and
waiting list time). The nearest available matching on the











Age (years) 51.9 (13.5) 52.7 (11.0) 0.578 52.0 (13.4) 52.2 (11.4) 0.928 0.016
Gender (male:female) 1:1 1.9:1 0.011 0.9:1 1.1:1 0.839 0.056
Ethnicity:
Caucasian 68 (89.5) 263 (87.4) 64 (88.9) 62 (86.1) 0.085
Asian 6 (7.9) 28 (9.3) 6 (8.3) 6 (8.3) 0.000
Other 2 (2.6) 10 (3.3) 0.88 2 (2.8) 4 (5.6) 0.494 0.140
Height (cm) 169 (10) 170 (14) 0.8 169 (10) 169 (10) 0.950 0.000
Body mass index 25.2 (4.6) 27.5 (5.0) <0.001 25.2 (4.6) 25.1 (4.1) 0.853 0.023
Aetiology of liver disease:
Alcoholic cirrhosis 8 (10.5) 74 (24.6) 7 (9.7) 8 (11.1) 0.046
Hepatitis C cirrhosis 14 (18.4) 61 (20.3) 14 (19.4) 17 (23.6) 0.102
Primary biliary cirrhosis 14 (18.4) 41 (13.6) 14 (19.4) 14 (19.4) 0.000
Primary sclerosing cholangitis 13 (17.1) 25 (8.3) 12 (16.7) 13 (18.1) 0.037
NASH cirrhosis 6 (7.9) 20 (6.6) 6 (8.3) 7 (9.7) 0.049
Hepatitis B cirrhosis 2 (2.6) 15 (5.0) 2 (2.8) 3 (4.2) 0.076
Autoimmune hepatitis 4 (5.3) 10 (3.3) 4 (5.6) 3 (4.2) 0.065
Other 15 (19.7) 55 (18.3) 0.077 13 (18.1) 7 (9.7) 0.273
Hepatocellular carcinoma 15 (19.7) 76 (25.2) 0.316 14 (19.4) 14 (19.4) 1.000 0.000
MELD score 17 (8) 16 (7) 0.24 16 (7) 17 (8) 0.440 0.127
UKELD 52 (7) 51 (6) 0.577 51 (7) 52 (7) 0.460 0.133
Regraft 4 (5.3) 12 (4.0) 0.408 0 (0) 0 (0) 0.000
Measures of renal function
Creatinine (lM) 81 (65–96) 85 (67–99) 0.201 80 (22) 82 (25) 0.654 0.085
eGFR (ml/min/1.73 m2) 90 (40) 89 (34) 0.759 91 (41) 90 (34) 0.870 0.027
Sodium (mM) 138 (136–141) 138 (134–140) 0.144 138 (136–141) 137 (135–140) 0.626 0.067
Haemodialysis 0 (0) 0 (0) 1 0 (0) 0 (0) NA* 0.000
Ascites 33 (43.4) 176 (58.5) 0.018 32 (44.4) 37 (51.4) 0.473 0.140
Refractory ascites 7 (9.2) 60 (19.9) 0.029 6 (8.3) 10 (13.9) 0.424 0.179
Hepatorenal syndrome (type 2) 0 (0) 7 (2.3) 0.204 0 (0) 1 (1.4) NA* 0.169
Co-morbidity
Diabetes mellitus 13 (17.1) 74 (24.6) 0.167 12 (16.7) 15 (20.8) 0.648 0.105
Insulin-dependent diabetes 9 (11.8) 34 (11.3) 0.893 9 (12.5) 8 (11.1) 1.000 0.040
Hypertension 13 (17.1) 42 (14.0) 0.487 12 (16.7) 11 (15.3) 1.000 0.038
Waiting list time (days) 59 (22–173) 71 (25–185) 0.638 59 (25–174) 53 (26–167) 0.904 0.000
Followup time (days) 962 (507–1323) 880 (449–1364) 0.894 932 (445–1271) 666 (314–1314) 0.373 0.000
Values expressed as mean (standard deviation), median (interquartile range) and number (per cent) where appropriate. Follow-up time defined as
duration from transplant to present day (patients not censored at time of death or regraft).
*P value incalculable due to the small sample size.
Significant values are shown in bold.
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estimated PRS method was used to construct the control
group with a caliper width of 0.2 of the standard deviation
of the logit of the propensity score [31,33]. Balance was
achieved between the SLT and FSLT groups on the
recognised confounders only when the single statistically
significant interaction term was excluded from the model
(Table 1) [34].
Pre-PRS matching, normally distributed continuous
variables and nonparametric continuous variables were
compared using the Student’s t-test and Mann–Whitney
test, respectively. Chi-squared analysis or Fisher’s exact test
were used for comparison of categorical data. After PRS
matching, the paired t-test was used with nonparametric
variables transformed into their natural logarithms and the
McNemar test’s for dichotomous variables. Survival was
estimated using Kaplan–Meier plots with log-rank test for
differences. Cumulative incidence of chronic kidney disease
was estimated using the Kaplan–Meier method. Variables
associated with AKI and renal replacement therapy were
assessed in the propensity score-matched patients using
backward sequential logistic regression of clinically relevant
variables. SLT status was forced into the final model to
determine any association with renal dysfunction. To
account for the superior donor quality of the SLT grafts,
the relationship between SLT and renal outcomes was then
determined in patient subgroups, stratified according to
the median values of the donor indices that differed most
between SLT and FSLT recipients. In these logistic regres-
sion models, SLT status and the statistically significant vari-
ables in the entire PRS-matched cohort were included
simultaneously. Cox proportional hazards analysis was
used to examine the relationship between SLT and chronic
kidney disease. P < 0.05 was considered statistically signifi-
cant unless otherwise stated.
Data were analysed using the SPSS (SPSS Inc., Chicago, IL,
USA) 18 package. All values are expressed as mean and
standard deviation (SD), and median and interquartile
range (IQR) as appropriate.
Results
Unmatched patients
Baseline clinical characteristics of all SLT and
unmatched FSLT patients are outlined in Table 1. SLT
recipients were more likely to be female (P = 0.011), to
have cholestatic disease (SLT, 38.2%; FSLT, 24.9%;
P = 0.021) and had a lower BMI (P < 0.001). Serum
creatinine (P = 0.201) and serum sodium (P = 0.144)
were similar for both groups. SLT patients were less
likely to have refractory ascites (P = 0.029), although
the prevalence of type 2 hepatorenal syndrome was the
same (P = 0.204). The frequency of an eGFR <60, 60–
89 and ≥90 ml/min/1.73 m2 was 13.9%, 47.2% and
38.9% for SLT patients, respectively, and 18.3%, 43.9%
and 37.9% for FSLT patients (P = 0.659).
The overall incidence of AKI in SLT recipients (n = 76)
was 43.4%, and in FSLT recipients (n = 301) was 55.8%
(P = 0.053). When regrafts were excluded SLT patients
(n = 72) were less likely than FSLT patients (n = 289) to
develop AKI (SLT, 40.3%; FSLT, 56.1%; P = 0.016). SLT
recipients demonstrated a lower frequency of renal replace-
ment therapy (SLT, 11.8%; FSLT, 21.9%, P = 0.049).
PRS-matched patients
In view of the differing baseline clinical characteristics of
the two groups, more detailed analyses were then per-
Table 2. Donor, graft and intra-operative characteristics of split liver










Height (cm) 175 (12) 167 (9) <0.001
AST (u/l) 38 (21–64) 42 (24–85) 0.664









4/26 (15.4) 10/54 (18.5) 0.625
Cold ischaemic
time (hours)




38.9 (8.6) 40.5 (6.2) 0.246








2 (0–3) 2 (0–3) 0.653
FFP transfusion
(units)




5 (0–10) 5 (0–10) 0.594
Inotropes 51 (70.8) 50 (69.4) 1.000
N-acetylcysteine 1 (1.4) 5 (6.9) 0.219
Values expressed as mean (standard deviation), median (interquartile
range) and number (per cent) where appropriate.
*P value incalculable due to the small sample size.
Significant values are shown in bold.
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formed comparing the renal outcomes of SLT patients
(n = 72) with a PRS-matched control group of FSLT
patients (n = 72). The groups were matched with regard to
recipient characteristics (Table 1). Donor and graft charac-
teristics are outlined in Table 2. When compared with
FSLT patients, the SLT recipients had a younger donor age
(P < 0.001), a trend towards a longer cold ischaemic time
(P = 0.056) but similar recipient warm ischaemic time
(P = 0.246). DRI excluding split status was lower in the
SLT group (P < 0.001).
There was no difference in the proportion of SLT and
FSLT patients who were prescribed renal sparing immuno-
suppression immediately post-transplant (SLT, 13.9%;
FSLT, 18.1%, P = 0.648) or at time of hospital discharge
(SLT, 24.3%; FSLT, 34.3%, P = 0.248). Tacrolimus trough
levels at day 7 (SLT, 7.6 (3.9) lg/l; FSLT, 8.1 (4.2) lg/l,
mean (SD); P = 0.423), day 30 (SLT, 7.2 (4.0) lg/l; FSLT,
7.1 (3.4) lg/l, mean (SD); P = 0.878) and 12 months
(SLT, 6.1 (2.7) lg/l; FSLT, 6.5 (2.6) lg/l, mean (SD);
P = 0.330) were similar (P < 0.017 considered significant).
Nonrenal morbidity and graft and patient survival
During the immediate postoperative period, the median
peak serum AST was 1156 (IQR 757–1675) u/l for SLT
recipients and 1124 (IQR 699–2239) u/l for FSLT controls
(P = 0.828). The frequency of re-laparotomy for bleeding
(SLT, 1.4%; FSLT, 4.2%; P = 0.625), primary nonfunction
(SLT, 1.4%; FSLT, 1.4%; P = 1.000), hepatic artery throm-
bosis (SLT, 1.4%; FSLT, 0%; P value incalculable), sepsis
(SLT, 16.7%; FSLT, 13.9%; P = 0.791) and biliary compli-
cations (SLT, 5.6%; FSLT, 5.6%; P = 1.000) were compara-
ble in both groups. The estimated 1-year and 3-year graft
survival were 87.3% and 85.5% for the SLT patients respec-
tively, and 92.6% and 90.4% for the FSLT controls (log
rank P = 0.292).
Duration of ITU stay (SLT, 3 (2–4) days; FSLT, 3 (2–5)
days, median (IQR); P = 0.300) and hospital stay (SLT, 11
(9–14) days; FSLT, 11 (9–18) days, median (IQR);
P = 0.062) were comparable for the two cohorts. An equal
proportion of SLT patients (95.8%) and FSLT patients
(95.8%) survived to hospital discharge (P = 1.000). Esti-
mated 1- and 3-year patient survival were 90.0% and
88.2% for SLT patients, respectively, and 94.0% and 91.8%
for FSLT controls (log rank P = 0.400).
Peri-operative renal function
Baseline serum creatinine (P = 0.654), eGFR (P = 0.870),
serum sodium (P = 0.626), and the prevalence of ascites
(P = 0.473), refractory ascites (P = 0.424) and type 2 he-
patorenal syndrome (P value incalculable) were the same
for both SLT and FSLT groups (Table 1).
Immediately after transplantation the median peak peri-
operative serum creatinine was 113 (IQR 85–177) lM for
SLT patients and 116 (IQR 81–223) lM for FSLT controls
(P = 0.415). The median peak peri-operative change in
serum creatinine from baseline was +27.0 (IQR 11.9–145.1)
% for SLT patients and +43.6 (IQR 6.8–197.3) % for FSLT
patients (P = 0.721). 40.3% of SLT patients developed AKI
compared with 47.2% of FSLT controls (P = 0.473, Fig. 1).
Table 3. Logistic regression analysis of variables associated with peri-
operative acute kidney injury after first elective donation after brain
death liver transplantation in propensity score-matched patients.
OR 95% CI P value
Pretransplant refractory ascites 3.96 1.15–13.69 0.030
≥5 units RCC intra-operative 5.01 1.63–15.40 0.005
Log peak postoperative AST (u/l) 2.11 1.25–3.54 0.005
SLT 0.76 0.37–1.56 0.454
Reference group (relative risk 1.00): No refractory ascites, 0–4 units
RCC intra-operative, FSLT recipient.
Additional variables entered into the model: age, pretransplant eGFR,
pretransplant MELD.
Significant values are shown in bold.
Figure 1 Stacked bar graph demonstrating the proportion of split liver
transplant recipients (SLT) and full-size liver transplant recipients (FSLT)
who developed acute renal dysfunction during the immediate postoper-
ative period. Renal dysfunction defined according to KDIGO criteria as:
Stage 1, rise in serum creatinine by ≥26.5 lM in <48 h and/or peak
serum creatinine 1.5–1.9 times baseline; Stage 2, peak serum creatinine
2.0–2.9 times baseline; Stage 3, peak serum creatinine ≥3.0 times base-
line and/or increase in serum creatinine ≥353.6 lM and/or renal replace-
ment therapy. P = 0.743.
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On multivariate analysis, there was no association between
SLT and AKI (OR 0.76; 95% CI 0.37–1.56, P = 0.454,
Table 3).
On univariate analysis, there was a trend towards less
renal replacement therapy in the SLT group (SLT, 11.1%;
FSLT, 23.6%, P = 0.078). The median renal replacement
therapy duration was 19 (IQR 3–34) days for SLT patients
and 6 (IQR 4–15) days for FSLT patients. On multivariate
analysis, SLT patients were less likely to require renal
replacement therapy (OR 0.32; 95% CI 0.11–0.87,
P = 0.026, Table 4).
Given the superior donor quality of the SLT grafts, the
relationship between SLT and renal outcomes was deter-
mined in patient subgroups, stratified according to the donor
indices that differed most between SLT and FSLT recipients
(Table 5). The frequency of renal outcomes was higher in
patients who received an older donor liver (AKI, P = 0.022;
renal replacement therapy, P = 0.002) and a higher DRI
(excluding split status) graft (AKI, P = 0.006; renal replace-
ment therapy, P = 0.009). When the patients were stratified
based on these donor quality indices, SLT was no longer
associated with a reduced risk of renal replacement therapy
(donor age <38 years, P = 0.593; donor age ≥38 years,
Table 4. Logistic regression analysis of variables associated with renal
replacement therapy after first elective donation after brain death liver
transplantation in propensity score-matched patients.
OR 95% CI P value
Age (years) 1.06 1.01–1.12 0.023
≥5 units RCC intra-operative 6.04 1.89–19.31 0.002
Log peak postoperative AST (u/l) 2.14 1.12–4.10 0.022
SLT 0.32 0.11–0.87 0.026
Reference group (relative risk 1.00): 0–4 units RCC intra-operative, FSLT
recipient.
Additional variables entered into the model: pretransplant eGFR, pre-
transplant MELD, pretransplant refractory ascites.
Significant values are shown in bold.
Table 5. Adjusted association between split liver transplantation and
peri-operative renal outcomes (acute kidney injury and renal replace-
ment therapy) in patient subgroups.
No (%)
with renal
outcome OR(95% CI)* P value
Acute kidney injury
Donor age <38 years 26 (34.7) 0.82 (0.23–2.94) 0.765
Donor age ≥38 years 37 (53.6)** 1.96 (0.56–6.84) 0.290
Donor risk index <1.60 32 (45.1) 0.58 (0.18–1.86) 0.360
Donor risk index ≥1.60 30 (42.9) 0.65 (0.22–1.95) 0.439
Donor risk index excluding
split status <1.22
24 (32.9) 0.74 (0.20–2.74) 0.647
Donor risk index excluding
split status ≥1.22
38 (55.9)*** 3.11 (0.82–11.83) 0.097
Renal replacement therapy
Donor age <38 years 6 (8.0) 2.05 (0.15–28.59) 0.593
Donor age ≥38 years 19 (27.5)** 0.32 (0.07–1.50) 0.148
Donor risk index <1.60 12 (16.9) 0.09 (0.01–1.05) 0.055
Donor risk index ≥1.60 13 (18.6) 0.29 (0.08–1.07) 0.062
Donor risk index excluding
split status <1.22
7 (9.6) 0.54 (0.07–4.32) 0.564
Donor risk index excluding
split status ≥1.22
18 (26.5)*** 0.51 (0.12–2.32) 0.368
Cut-off values for subgroups were based on the median of the PRS-
matched patients.
*Adjusted for refractory ascites, ≥5 units RCC intra-operative and log
peak postoperative AST (u/l) when the renal outcome is acute kidney
injury and adjusted for age (years), ≥5 units RCC intra-operative and log
peak postoperative AST (u/l) when the renal outcome is renal replace-
ment therapy.
**P < 0.05 for renal outcome in donor age ≥38 years vs. <38 years
groups.
***P < 0.05 for renal outcome in donor risk index excluding split status
≥1.22 vs. <1.22 groups.
Table 6. Cox regression analysis of variables associated with chronic
kidney disease after first elective donation after brain death liver trans-
plantation in propensity score-matched patients.
OR 95% CI P value
Age (years) 1.05 1.01–1.09 0.021
Pretransplant eGFR 0.99 0.97–1.00 0.080
SLT 1.18 0.59–2.36 0.649
Reference group (relative risk 1.00): FSLT recipient.
Additional variables entered into the model: pretransplant MELD, pre-
transplant diabetes mellitus, day 7 tacrolimus trough.
Significant values are shown in bold.
Figure 2 Cumulative incidence of stage 3–5 chronic kidney disease fol-
lowing liver transplantation subdivided into split liver transplantation
recipients (SLT) and full-size liver transplantation recipients (FSLT).
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P = 0.148; DRI <1.22, P = 0.564; DRI ≥1.22, P = 0.368).
This suggests that donor quality may underlie the lower rate
of renal replacement therapy in SLT recipients.
Long-term renal function post-transplant
By 1 month post-transplant the mean eGFR was similar in
SLT and FSLT patients (SLT, 83 [35] ml/min/1.73 m2;
FSLT, 81 (37) ml/min/1.73 m2, mean (SD), P = 0.688).
Furthermore, the mean change in eGFR by 12 months
from baseline was no different for the two groups (SLT,
11.5 (29.2) %; FSLT, 13.7 (31.3) %, mean (SD),
P = 0.599). The cumulative incidence of stage 3–5 chronic
kidney disease by 3 years post-transplant was 32.5% and
28.7% for SLT and FSLT patients, respectively (log rank
P = 0.534, Fig. 2). No SLT or FSLT patient fulfilled the cri-
teria for severe chronic kidney (stage 4–5) during the fol-
low-up period. On multivariate analysis, there was no
association between SLT and CKD (HR 1.18; 95% CI 0.59–
2.36, P = 0.649, Table 6).
Discussion
In this large contemporary single-centre study, we have exam-
ined in detail the renal consequences of SLT for the adult reci-
pient. We have shown that SLT patients had a lower
incidence of peri-operative AKI than FSLT patients trans-
planted in the same time period. Importantly, when
compared with a well-matched FSLT cohort, demonstrating a
similar rate of graft-related complications, the SLT group had
at least equivalent renal outcomes. SLT recipients had a com-
parable frequency of AKI to PRS-matched FSLT controls, but
were less likely to require renal replacement therapy.
AKI after liver transplantation is multifactorial in origin.
Pretransplant neuro-humoral and circulatory derangement,
and intrinsic chronic kidney disease, predisposes patients
with end-stage liver failure to acute renal dysfunction [35].
Intra-operatively, hemodynamic insults including surgical
technique and haemorrhage culminate in renal ischaemia,
inflammation and injury [11,12,36]. Thereafter, the
administration of a calcineurin inhibitor further compro-
mises renal perfusion and function [37].
The role of the graft in the pathogenesis of AKI after
liver transplantation is less well recognised. Hepatic ischae-
mia–reperfusion injury is accompanied by a systemic inflam-
matory response, which may cause AKI through
hemodynamic mechanisms and direct tubular cell death [38–
42]. Liver transplant recipients with ischaemia–reperfusion
injury are more likely to develop peri-operative renal dysfunc-
tion and to require haemodialysis [43,44]. Moreover, the
added donor warm ischaemic time and greater injury of
DCD liver transplantation is associated with an increased fre-
quency of AKI [14]. It follows that graft injury, by driving a
systemic inflammatory response, is a contributing factor in
post-transplant AKI.
In SLT, the ex situ dissection prolongs the cold ischaemic
time and potentially exposes the graft to additional warm
ischaemia via manipulation [45]. Therefore, it might be antic-
ipated that SLT grafts display greater ischaemia–reperfusion
injury. On the other hand, SLT uses ideal quality organs
sourced from optimal donors [5,46,47]. Younger age and lack
of steatosis are known to have a favourable effect on hepatic
ischaemia–reperfusion injury [48,49]. Other factors that may
influence renal outcomes in SLT include the reported
increased rate of hepatic artery thrombosis, biliary complica-
tions and sepsis, and small for size syndrome [6,19,50–52].
In this study, we have shown that when SLT recipients were
compared with well-matched FSLT controls the immediate
postoperative course was similar, including the frequency of
graft-related complications. In this setting, the SLT group did
not demonstrate an increased rate of AKI. Indeed, there was a
suggestion of reduced renal injury considering the patient
numbers, with a lower rate of renal replacement therapy.
Where SLT and matched FSLT patients differed was in donor
selection. SLT donors were younger and had a lower DRI if the
split status was excluded. AKI was more frequent in recipients
of grafts from older donors and with a higher DRI. Moreover,
when patients were stratified into subgroups according to these
donor quality indices, SLT was no longer associated with a
reduced risk of renal replacement therapy. Such observations
support the postulation that the optimal donor status of SLT
may result in less graft injury with renal sparing effects.
It is noteworthy that the definition of AKI applied here
has not been used previously in assessing renal injury after
liver transplantation and may have influenced the results.
We defined AKI as recommended by the recently issued
guidelines by KDIGO and the Acute Dialysis Quality Initia-
tive-International Ascites Club Working Party [28,29]. The
frequency of acute renal injury and failure in our FSLT
recipients when defined according to the RIFLE criteria was
comparable to other reports [11,12].
Increasing severity of AKI is associated with increasing
risk of chronic kidney disease, whilst AKI patients who
require renal replacement therapy and then recover are at
particularly high risk of progression to chronic renal
impairment [53]. It is therefore perhaps surprising that,
despite the reduced frequency of renal replacement ther-
apy in SLT recipients, we did not observe any difference
in the incidence of chronic kidney disease. We believe the
relatively short duration of follow-up explains the failure
to observe a beneficial effect on long-term renal function.
The study has some additional potential limitations that
should be mentioned. Firstly, the retrospective nature of
the study meant that the frequency of peri-operative creati-
nine measurement was variable. All patients had blood
sampling immediately on arrival to the Intensive Care Unit
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and, in most cases, 12 hourly for the first 24 to 48 h. It is
possible, for example, that the peak creatinine underesti-
mated the severity of renal injury. Secondly, nephrotoxic
medication could have influenced the severity of AKI and
development of chronic kidney disease. Our unit avoids
nephrotoxic drugs during the peri-operative period but this
does not preclude exposure after discharge. All patients
were under regular outpatient review, and there were no
documented drug-induced adverse renal events. Thirdly,
the lack of pretransplant renal impairment may raise some
concerns about the generalizability of the results for some
populations of liver transplant recipients. Nevertheless, the
study cohort is typical of those who undergo single organ
liver transplantation in many countries.
Our findings have important implications for patient
care. SLT recipients should not be considered a high risk
group for developing AKI during the immediate postopera-
tive period. Consequently, renal sparing immunosuppres-
sion should be reserved for select individuals only. The at
least comparable renal outcomes to FSLT controls add fur-
ther weight to the argument that SLT is a valuable resource
to expand the donor pool.
In conclusion, in this large single-centre case-controlled
study, we have shown that SLT is not associated with an
increased frequency of AKI. Our observations support the
postulation that the optimal donor status of SLT may result
in less graft injury with renal sparing effects.
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